OXIS International Reports October Revenues Match Total 3rd Quarter Revenues
BEVERLY HILLS, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- via PRWEB - OXIS
International, Inc., (OXIS) (OXI.PA) today announced revenues for October were
in excess of $105,000. This represents a threefold increase in the average
monthly revenue for the 3rd quarter.
David Saloff, OXIS Chairman and CEO stated, "We are extremely pleased with the
continued strong revenue growth in October. Both initial and reorders of our
products, Prograce (http://www.prograceyou.com) and Reverge
(http://www.revergeyou.com) have increased significantly and exceeded the
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research,
diagnose, treat and prevent diseases of oxidative stress/inflammation
associated with damage from free radical and Reactive Oxygen Species (ROS).
The company holds the exclusive patent to manufacture EGT, which has received
full GRAS (safety) approval. In addition the company holds the rights to
several therapeutic classes of compounds in the area of oxidative stress,
including EGT(TM) (99% pure L-ergothioneine), known as the intelligent
This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit
CONTACT: OXIS International
Press spacebar to pause and continue. Press esc to stop.